“There is a growing list of approved targets and therapies included in the 2018 NCCN Guidelines for Non–Small Cell Lung Cancer [NSCLC] as well as emerging targets. Why does this matter? Because targeted therapies improve survival,” said Karen L. Reckamp, MD, MS, Co-Director, Lung Cancer and Thoracic Oncology Program, and Professor, City of Hope Comprehensive Cancer Center.
“With no targeted therapy, median survival for a select group of patients with NSCLC is 2 years. If there is an oncologic driver and no targeted therapy is given, median overall survival [OS] is approximately 2 years. But, when there is an oncologic driver and targeted therapy is given, median OS jumps to over 3 years,” she told the audience at the NCCN 23rd Annual Conference.1
The list of mutations with approved targeted therapies includes EGFR mutations (present in 30%–40% of Asians2 and 10%–20% of Caucasians),3 ALK rearrangements (present in up to 7%), ROS1 rearrangements (1.7%), and BRAF mutations (present in 2%). Other targets with therapies that are not approved for use in NSCLC include HER2 (present in 2%), RET (present in 1.7%), MET (present in 10%), and NTRK (present in <1%).
The 2018 NCCN Guidelines recommend molecular testing to make the initial diagnosis, and this is then followed by PD-L1 testing. For adenocarcinoma, testing is recommended for EGFR, ALK, ROS1, and BRAF mutations as part of broad molecular profiling, in addition to PD-L1 testing. For squamous cell carcinoma, the recommendation is to consider testing for the same 4 mutations in a subset of patients and to perform PD-L1 testing in all patients.
Dr. Reckamp has disclosed that she has received grant/research support from AbbVie; ACEA; Adaptimmune; ARIAD Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Genentech, Inc.; Guardant; Loxo Oncology; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Seattle Genetics; and Xcovery. She has also received consulting fees/honoraria from Amgen Inc., ARIAD Pharmaceuticals, Inc., Astellas, Euclises, and Tesaro, Inc.
Kris MG, Johnson BE, Berry LD et al. . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 2014;11:1998–2006.
Mok TS, Wu YL, Thongprasert S et al. . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
Rosell R, Moran T, Queralt C et al. . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–967.
Wu YL, Cheng Y, Zhou X et al. . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomized, open-label, phase 3 trial. Lancet Oncol 2017;11:1454–1466.
Soria JC, Ohe Y, Vansteenkiste J et al. . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–125.
Peters S, Camidge DR, Shaw AT et al. . Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829–838.
Hida T, Nokihara H, Kondo M et al. . Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29–39.
Drilon A, Laetsch TW, Kummar S et al. . Efficacy of lacotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.